Using two new orally available MK2 inhibitors, TBX-1 and TBX-2, we now report that MK2 inhibitor treatment of Ldlr-/- mice with established atherosclerosis improves metabolism and features of unstable plaques. The gene discussed is MAPKAPK2; the disease is atherosclerosis.